Our data accentuate the prognostic value of PAI‐1 and the potential to repurpose existing drugs, such as tenecteplase, to treat the hypofibrinolytic state in COVID‐19 and other acute respiratory diseases. The gene discussed is SERPINE1; the disease is COVID-19.